A modular and multi-functional purification strategy that enables a common framework for manufacturing scale integrated and continuous biomanufacturing

被引:1
作者
Pybus, Leon P. [1 ]
Heise, Charles [1 ]
Nagy, Tibor [1 ]
Heeran, Carmen [1 ]
Dover, Terri [1 ]
Raven, John [1 ]
Kori, Junichi [2 ]
Burton, Graeme [1 ]
Sakuyama, Hiroshi [2 ]
Hastings, Benjamin [1 ]
Lyons, Michelle [1 ]
Nakai, Shinichi [2 ]
Haigh, Jonathan [1 ]
机构
[1] FUJIFILM Diosynth Biotechnol, Proc Dev, Billingham, England
[2] FUJIFILM Corp, Bio Sci & Engn Labs, Kaisei, Japan
关键词
Chinese hamster ovary; downstream processing; integrated and continuous biomanufacturing; mAb bioprocessing; perfusion; upstream processing; TANGENTIAL FLOW FILTRATION; CATION-EXCHANGE CHROMATOGRAPHY; VIRUS FILTRATION; THROUGH PURIFICATION; CULTURE PROCESSES; PROTEIN; PERFUSION; PH; DESIGN; FEASIBILITY;
D O I
10.1002/btpr.3456
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Biopharmaceutical manufacture is transitioning from batch to integrated and continuous biomanufacturing (ICB). The common framework for most ICB, potentially enables a global biomanufacturing ecosystem utilizing modular and multi-function manufacturing equipment. Integrating unit operation hardware and software from multiple suppliers, complex supply chains enabled by multiple customized single-use flow paths, and large volume buffer production/storage make this ICB vision difficult to achieve with commercially available manufacturing equipment. Thus, we developed SymphonX (TM), a downstream processing skid with advanced buffer management capabilities, a single disposable generic flow path design that provides plug-and-play flexibility across all downstream unit operations and a single interface to reduce operational risk. Designed for multi-product and multi-process cGMP facilities, SymphonX (TM) can perform stand-alone batch processing or ICB. This study utilized an Apollo (TM) X CHO-DG44 mAb-expressing cell line in a steady-state perfusion bioreactor, harvesting product continuously with a cell retention device and connected SymphonX (TM) purification skids. The downstream process used the same chemistry (resins, buffer composition, membrane composition) as our historical batch processing platform, with SymphonX (TM) in-line conditioning and buffer concentrates. We used surge vessels between unit operations, single-column chromatography (protein A, cation and anion exchange) and two-tank batch virus inactivation. After the first polishing step (cation exchange), we continuously pooled product for 6 days. These 6 day pools were processed in batch-mode from anion exchange to bulk drug substance. This manufacturing scale proof-of-concept ICB produced 0.54 kg/day of drug substance with consistent product quality attributes and demonstrated successful bioburden control for unit-operations undergoing continuous operation.
引用
收藏
页数:17
相关论文
共 104 条
  • [1] Green metrics for biologics
    Argoud, Sarah
    Budzinski, Kristi
    D'Aquila, Daniel
    Madabhushi, Sri R.
    Smith, Phillip
    [J]. CURRENT OPINION IN GREEN AND SUSTAINABLE CHEMISTRY, 2022, 35
  • [2] Implementation of Fully Integrated Continuous Antibody Processing: Effects on Productivity and COGm
    Arnold, Lindsay
    Lee, Kenneth
    Rucker-Pezzini, Joanna
    Lee, Jeong H.
    [J]. BIOTECHNOLOGY JOURNAL, 2019, 14 (02)
  • [3] Investigation of single-pass tangential flow filtration (SPTFF) as an inline concentration step for cell culture harvest
    Arunkumar, Abhiram
    Singh, Nripen
    Peck, Michael
    Borys, Michael C.
    Li, Zheng Jian
    [J]. JOURNAL OF MEMBRANE SCIENCE, 2017, 524 : 20 - 32
  • [4] Bain David, 2015, PDA J Pharm Sci Technol, V69, P451, DOI 10.5731/pdajpst.2015.01070
  • [5] Effect of solution pH on protein transmission and membrane capacity during virus filtration
    Bakhshayeshi, Meisam
    Zydney, Andrew L.
    [J]. BIOTECHNOLOGY AND BIOENGINEERING, 2008, 100 (01) : 108 - 117
  • [6] Contribution of protein A step towards cost of goods for continuous production of monoclonal antibody therapeutics
    Bansode, Vikrant
    Gupta, Paridhi
    Kateja, Nikhil
    Rathore, Anurag S.
    [J]. JOURNAL OF CHEMICAL TECHNOLOGY AND BIOTECHNOLOGY, 2022, 97 (09) : 2420 - 2433
  • [7] Barone Paul W, 2019, PDA J Pharm Sci Technol, V73, P191, DOI 10.5731/pdajpst.2018.008862
  • [8] Downstream process development strategies for effective bioprocesses: Trends, progress, and combinatorial approaches
    Baumann, Pascal
    Hubbuch, Juergen
    [J]. ENGINEERING IN LIFE SCIENCES, 2017, 17 (11): : 1142 - 1158
  • [9] Model assisted comparison of Protein A resins and multi-column chromatography for capture processes
    Baur, Daniel
    Angelo, James M.
    Chollangi, Srinivas
    Xu, Xuankuo
    Muller-Spath, Thomas
    Zhang, Na
    Ghose, Sanchayita
    Li, Zheng Jian
    Morbidelli, Massimo
    [J]. JOURNAL OF BIOTECHNOLOGY, 2018, 285 : 64 - 73
  • [10] Comparison of batch and continuous multi-column protein A capture processes by optimal design
    Baur, Daniel
    Angarita, Monica
    Muller-Spath, Thomas
    Steinebach, Fabian
    Morbidelli, Massimo
    [J]. BIOTECHNOLOGY JOURNAL, 2016, 11 (07) : 920 - 931